GlassScriptPhysician profile
Carmelo L Roco
NPI 1316996465
$15,079.24
in general payments reported to CMS, 2019-2025
39 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,122 · 2020: $2,811 · 2021: $3,689 · 2022: $1,968 · 2023: $1,528 · 2024: $1,495 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,594.02 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $1,667.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $939.43 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $898.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $826.01 | 2019-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $628.11 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $455.47 | 2019-2023 | Verquvo |
| Pfizer INC. | $432.64 | 2019-2023 | |
| Merz North America, INC. | $429.15 | 2019-2025 | Xeomin |
| Amarin Pharma, INC. | $417.75 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $393.83 | 2019-2022 | |
| Lilly USA, LLC | $389.95 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $363.29 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $344.73 | 2019-2024 | |
| Amgen INC. | $340.50 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Roco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.